News Releases

Allergan to Present Dynamic Eye Care Data at American Academy of Ophthalmology Meeting in New Orleans

DUBLIN, Nov. 8, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced its data will be presented at the annual American Academy of Ophthalmology (AAO) meeting in New Orleans, Louisiana, November 11 – 14, 2017.

Allergan plc logo

"Allergan is proud of the breadth of data being presented at this year's AAO meeting," said David Nicholson, executive vice president and Chief R&D Officer at Allergan. "This clinical data underscores our commitment to developing and bringing to market innovative treatments for unmet diseases and conditions of the eye that impact millions of patients globally."

The scheduled times (noted in local Central Time) and locations of the eight Allergan data presentations at the New Orleans Ernest N. Morial Convention Center are as follows:

Dry Eye

  • Intranasal Tear Neurostimulation for Subjects with Dry Eye Disease: Results from Two Pivotal Clinical Trials
    • Date and Time: Sunday, November 12, 2017, 2:24 PM2:31 PM
    • Session: PA022
    • Location: 255-257
    • Authors: E. Holland, S. Baba, M. Senchyna and M. Holdbrook


  • Total Tear Lipid and Total Protein Concentrations Following Intranasal Tear Neurostimulation in Subjects with Dry Eye
    • Date and Time: Sunday, November 12, 2017, 12:45 PM1:45 PM
    • Session: PO062
    • Location: Hall C
    • Authors: S. Lee, M. Senchyna, M. Kamat and S. Baba


  • Real-World Injection Patterns of Anti-VEGF Agents in Neovascular AMD
    • Date and Time: Sunday, November 12, 12:45 PM1:45 PM
    • Session: PO213
    • Location: Hall C
    • Authors: A. Almony and J. Campbell


  • 24-Month Phase 1/2 Clinical Trial of Bimatoprost Sustained-Release Implant in Glaucoma Patients
    • Date and Time: Monday, November 13, 3:30 PM3:37 PM CT
    • Session: PA063
    • Location:  271-273
    • Authors: R. Craven, T. Walters, W. Christie, D. Day, R. Lewis, M. Goodkin, M. Chen and M. Bejanian


  • A Novel OCT Iridocorneal Angle Assessment Compared to Gonioscopy in OAG and OHT Patients
    • Date and Time: Monday, November 13, 2017 2:36 PM2:43 PM CT
    • Session: PA059
    • Location: 271-273
    • Authors: R. Craven, S. Xinghuai, H. Schenker, R. Saltzmann, S. Lee and M. Checn


  • Reduction in IOP From a Sustained-Release Bimatoprost Ring: Pooled Results from Two Open-label Extension (OLE) Studies
    • Date and Time: Friday, October 13 2:00 PM3:15 PM CT
    • Location: Room 243 – 245  
    • Authors: J. Brandt, H. Dubiner, K. Sall, G. Walker and C. Semba


  • Patient Reported Outcome Results in the XEN 45 Gel Stent Pivotal Trial in Patients with Refractory Glaucoma 
    • Date and Time: Monday, November 13, 12:45 PM1:45 PM CT
    • Session: PO378
    • Location:  Hall C
    • Authors: J. Panarelli, A. Sheybani, M. Stiles, R. Lewis, M. Robinson, J. Ling, S. Lee


  • Healthcare Resource Utilization Following Trabeculectomy: An Analysis of English Hospital Episode Statistics Data
    • Date and Time: Sunday, November 12, 2017, 12:45 PM1:45 PM CT
    • Session: PO108
    • Location:  Hall C
    • Authors: A. Khawaja, I. Keyzor, K. Kishore, G. Unal and J. Campbell

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 65+ mid-to-late stage pipeline programs currently in development.

Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS: Allergan: 
Daphne Karydas 
(862) 261-8006

Mark Marmur 
(862) 261-7558

Suzanne Jacobson 
(201) 273-4724

SOURCE Allergan plc